BIO - BIO バイオ・ラッド・ラボラトリ―ズ （）

Victory Capital Management Inc. lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 36.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,768 shares of the medical research company’s stock after purchasing an additional 2,898 shares […]

If history is any guide, there may be trouble ahead for shares of Bio-Rad Laboratories (NYSE: BIO ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com

In September 2021, Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO). Northbrook, IL 60062 -- ( SBWIRE ) -- 05/17/2023 -- The multiplex assays industry is expected to experience significant growth in the near future. This is due to the increasing demand for multiplex assays in clinical and research settings. Multiplex assays are an efficient and cost-effective way to analyze multiple biomarkers in a single sample. This technology can be used to diagnose and monitor diseases, assess drug efficacy, and identify potential drug targets. Additionally, multiplex assays can be used to quickly diagnose and monitor infectious diseases, food safety, and environmental contaminants. As the demand for multiplex assays continues to increase, the industry is likely to experience further growth and innovation in the near future. Multiplex Assays Market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach $5.3 billion by 2027, growing at a CAGR of 8.8% from 2022 to 2027 according to a new report by MarketsandMarkets™.

NEWARK, DE / ACCESSWIRE / May 16, 2023 / The global Western Blotting Market is estimated to attain a valuation of US$ 980.1 Million in 2023 and is anticipated to reach US$ 1753.4 million by 2033, trailing a CAGR of 6% during the forecast period. The growing prevalence of Lyme and Human Immuno Deficiency (HIV) diseases in the region is a significant driver for market growth. Increased research activities, research and development investments by pharmaceutical and biotechnology companies, and advancements in the proteomics sector further contribute to market growth. The rise in industry-academic research collaborations and the growing demand for personalized medicine also play a role in influencing the market. The global Western Blotting market is expected to be driven by the increasing prevalence of HIV during the forecast period, as Western Blotting is predominantly utilized for HIV detection. For example, in January 2022, data from UNAIDS, a Joint United Nations Programme involved in Human Immuno Deficiency epidemiology data collection, indicated that 1.5 Million people were newly infected with HIV in 2021.

https://www.investing.com/news/pro/biorad-laboratories-inc-receives-investment-bank-analyst-rating-update-3075704

Related Stocks: NCR , PFE , IBM , BIO , VOD ,

Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…

Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com

Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million

Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…

Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com

Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million

Bio-Rad Labs (BIO) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close.The consensus EPS Estimate is $2.71 (-23.4% Y/Y) and the consensus…